Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase NA 2Phase 4 2Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Neoplasms 4Neoplasm Metastasis 3Melanoma 3Head and Neck Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Esophageal Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1NSCLC 1Meningeal Carcinomatosis 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Hematologic Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × Immune Checkpoint Inhibitors × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04625205 2025-04-06

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

BioNTech SE

Phase 1 Terminated
22 enrolled
Dermatologic

Melanoma

NCT02574533 2017-09-27

Pilot Study of Vigilâ„¢ + Pembrolizumab for Advanced Melanoma

Gradalis, Inc.

Phase 1 Completed
2 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡